Merlin Biosciences is pushing ahead with the float of a second biotech investment despite its first exit two months ago now standing nearly 20% below the issue price.

Merlin has hired ABN Amro Rothschild to float Microscience, a UK developer of vaccines which include a promising product to prevent travellers' diarrhoea.